Point72 Ventures Launches Healthcare Investing Business

Scott Barclay, seasoned healthcare investor and former DCVC partner, to build team and invest in founders transforming the future of healthcare

SAN FRANCISCO--(BUSINESS WIRE)-- Point72 Ventures, a VC firm backed by Steve Cohen that invests in early-stage companies that are catalyzing the future of their industries, today announced the launch of a new investment team focused on Healthcare. The effort will be led by seasoned computational healthcare investor Scott Barclay.

Point72 Ventures’ new Healthcare team will invest globally in early-stage founders with the hunger, vision, and unique capabilities to impact healthcare at scale. Barclay will build a team that combines deep technical expertise with a breadth of healthcare domain experience to make big bets on the future.

“The current healthcare system is broken, particularly in the United States,” said Matthew Granade, Managing Partner of Point72 Ventures. “We believe that these problems will be solved by technical founders who are dedicated to reimagining how the healthcare system should function at scale. We want to help them succeed in making these ideas come to life while building big successful businesses.”

“At Point72 Ventures, our goal is to be experts in the areas in which we invest,” Granade added. “Scott has a 15-year track record and real passion for working with innovative, healthcare-focused founders. He is the kind of expert-focused investor we want at Point72 Ventures, and we are thrilled to have him on board.”

Barclay has deep expertise in healthcare and the commercialization and scale of deep tech startups rooted in scientific advances and high-tech engineering innovation. Prior to joining Point72 Ventures, Scott was a Partner at Data Collective Venture Capital (DCVC), where he created and led the Computational Care practice that focused on backing companies pushing compute into healthcare. He invested in and served on the boards of numerous DCVC portfolio companies, including Carbon Health, Medical Informatics Corp and Freenome, to name a few. Prior to joining DCVC, he led operational and innovation teams at CVS Health, served as Chief Strategy and Product Officer of Surescripts, served as a consultant at The Boston Consulting Group, and established the capital markets desk in London for Montgomery Securities (later Bank of America Securities).

“We must bring a true entrepreneurial spirit, advanced computation and technology, scientific rigor, and a deep sense of empathy for the patient’s and practitioner’s journey to fix the broken healthcare system,” said Barclay. “I’m thrilled to join one of the smartest platforms in the world, backed by patient long-term capital, to build a purpose-driven, diverse team dedicated to backing founders with big ideas and technical expertise. It’s an honor to be here and I’m confident that our work will make a tremendous difference.”

The creation of Point72 Ventures’ Healthcare investment platform represents another milestone in the Firm’s focus on backing early-stage companies catalyzing key changes in the global economy. Since launching in 2016, the Firm has invested in more than 50 companies across the Financial Services, Artificial Intelligence and Enterprise Technology verticals.

About Point72 Ventures

Point72 Ventures is a global venture capital firm led by a diverse set of domain experts with the capital to lead rounds through all stages of a company's growth. The firm invests primarily in Fintech, AI/ML, Enterprise and Healthcare technologies. As an independent arm of Point72, the global asset management firm led by Steven A. Cohen, Point72 Ventures offers well-informed insights into the global economy. Point72 Ventures has offices in New York City, Palo Alto, California, and Stamford, Connecticut. For more information, visit their website at p72.vc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005667/en/

Media:
Tiffany Galvin-Cohen
(203) 609-3126
[email protected]

Source: Point72 Ventures

You May Also Be Interested In

• Materialise Reports First Quarter 2024 Results
• CC Industries Announces Acquisition of Foremark Performance Chemicals
• Lazard Reports First-Quarter 2024 Results